See the latest news and media coverage for Lakewood Amedex. We track all announcements, press releases, and industry mentions in real time, all in one place.
Antimicrobial drug developer
lakewoodamedex.comLast updated
In short: Lakewood Amedex dosed the first patient in its Nu-3 Phase 2a trial for infected diabetic foot ulcers and expanded its global IP portfolio.
Topical Bisphosphocin candidate demonstrates consistent bactericidal activity against resistant pathogens in clinical isolates. Phase 2a trial topline expected Q1 2027.
The letter to shareholders emphasizes transformational progress and outlines the strategic outlook for their antifibrotic therapy candidate focused on diabetic foot ulcers.
The company obtained IRB approval to test the drug for infected diabetic foot ulcers following positive preclinical data.
Nu-3 targets bacterial membranes with a high barrier to resistance, supporting the national action plan against antibiotic-resistant bacteria.
Intravesical administration of Bisphosphocin® Nu-8 in E. coli-infected rodents showed up to 97% E. coli growth...
Lakewood-Amedex Biotherapeutics Inc. stocks have been trading up by 41.32 percent amid heightened optimism over its latest ...
Lakewood-Amedex Biotherapeutics Inc. announced that the first patient had received treatment as part of its phase 2a clinical study evaluating Nu-3...
At its Sept. 22 annual meeting, Lakewood-Amedex Biotherapeutics shareholders approved an amendment increasing authorized common shares to 100 million from 12.5 million and authorized the...
Track Lakewood Amedex and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Lakewood Amedex and other trending companies.